Abstract:The aim of this study was to determine the long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the natural course of disease in chronic hepatitis B patients (CHB) with/without cirrhosis in clinical practice. A total of 355 treatment-naïve CHB patients were enrolled into the study. The primary outcome measure was viral suppression as defined by serum HBV DNA level <20 IU/mL. A secondary outcome measure was to determine the development of Hepatocellular carcinoma (HCC). Virological a… Show more
“…As for TDF, it has been indicated that the suppressive effect on HCC seems equivalent to ETV. 21,22 However, further study is necessary because there have only been a small number of reports. Thus, no obvious differences were found between different NA therapies in suppressing HCC among HBV-infected patients with or without cirrhosis.…”
Section: Impact Of Nucleos(t)ide Analogue For Hccmentioning
The development of nucleos(t)ide analogues (NA) has influenced hepatitis B virus management. However, the annual incidence rate during NA treatment has been reported to be 0.3-1.2% in non-cirrhosis cases and 1.8-6.0% in cirrhosis cases, indicating that the suppressive effect of NA treatment on hepatocellular carcinoma (HCC) would be insufficient. Past studies, including one randomized control trial that compared lamivudine treatment with placebo, have revealed that NA treatment could suppress the incidence of HCC in patients with advanced fibrosis. However, it remains unknown whether NA treatment can suppress the incidence of HCC in chronic hepatitis patients without advanced fibrosis. The HCC incidence in patients treated with entecavir was similar to that of those treated with lamivudine, although entecavir exhibits a stronger viral suppression than lamivudine. The following risk factors related to the incidence of HCC during NA treatment have been identified: older age, male gender, pre-existing cirrhosis, a family clustering of hepatitis B virus, lower platelet counts, and higher hepatitis B core-related antigens as baseline factors and higher alpha fetoprotein levels as an on-treatment factor. Conversely, the loss of the hepatitis B surface antigen (HBsAg) by interferon or NA was correlated with a lower HCC incidence rate. Because interferon treatment has much more effects on reducing HBsAg levels compared with NA treatment, a combination treatment with NA and pegylated interferon can bring additional reduction of HBsAg levels compared with NA monotherapy. Further study is needed to clarify this.
“…As for TDF, it has been indicated that the suppressive effect on HCC seems equivalent to ETV. 21,22 However, further study is necessary because there have only been a small number of reports. Thus, no obvious differences were found between different NA therapies in suppressing HCC among HBV-infected patients with or without cirrhosis.…”
Section: Impact Of Nucleos(t)ide Analogue For Hccmentioning
The development of nucleos(t)ide analogues (NA) has influenced hepatitis B virus management. However, the annual incidence rate during NA treatment has been reported to be 0.3-1.2% in non-cirrhosis cases and 1.8-6.0% in cirrhosis cases, indicating that the suppressive effect of NA treatment on hepatocellular carcinoma (HCC) would be insufficient. Past studies, including one randomized control trial that compared lamivudine treatment with placebo, have revealed that NA treatment could suppress the incidence of HCC in patients with advanced fibrosis. However, it remains unknown whether NA treatment can suppress the incidence of HCC in chronic hepatitis patients without advanced fibrosis. The HCC incidence in patients treated with entecavir was similar to that of those treated with lamivudine, although entecavir exhibits a stronger viral suppression than lamivudine. The following risk factors related to the incidence of HCC during NA treatment have been identified: older age, male gender, pre-existing cirrhosis, a family clustering of hepatitis B virus, lower platelet counts, and higher hepatitis B core-related antigens as baseline factors and higher alpha fetoprotein levels as an on-treatment factor. Conversely, the loss of the hepatitis B surface antigen (HBsAg) by interferon or NA was correlated with a lower HCC incidence rate. Because interferon treatment has much more effects on reducing HBsAg levels compared with NA treatment, a combination treatment with NA and pegylated interferon can bring additional reduction of HBsAg levels compared with NA monotherapy. Further study is needed to clarify this.
“…There was no significant difference found between the NA in the prevention of HCC. In a study of 355 treatment-naïve patients with CHB, 39.2% of whom had cirrhosis, who received entecavir or tenofovir, Idilman et al [33] found that the cumulative incidence of HCC at 1 year was 3.3% and at 4 years was 7.3%. No significant difference was found between the 2 groups.…”
Section: Impact Of Na Choice On Hcc Incidencementioning
How to cite this article: Ayoub WS, Dailey F, Martin P, Jones PD. The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings. Hepatoma Res 2017;3:302-8.Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women; HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year -half of which occur in China -and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of the deaths from HCC are associated with hepatitis B virus (HBV). Fortunately, HBV vaccination and antiviral therapy have shown excellent efficacy in decreasing the incidence of HCC. We will discuss the relationship of HBV to HCC, address available treatments for HBV and the impact of treatment on the development of HCC.
Key words:Liver cancer, hepatocellular carcinoma, hepatitis B, nucleos(t)ides, entecavir; tenofovir, lamivudine
ABSTRACTArticle history:
“…Yine bu çalışmada hastalık ciddiyetiyle (dekompanse siroz, kompanse siroz ve non-sirotik KHB) HSK riskinin arttığı gösterilmiştir. Bununla birlikte non-sirotik hastalarda da HSK (12). Sunulan olguda siroz yoktur ancak ileri yaş ve myelodisplastik sendromla ilişkilendirilmiş olsa da trombosit düşüklüğü gibi risk faktörleri bulunmaktaydı.…”
Kronik hepatit B tedavisinde amaç siroz, karaciğer yetmezliği ve hepatoselüler kanser (HSK) gelişmesi-nin önlenmesidir (1). Bu amaçlara ulaşmada hepatit B virusu (HBV) replikasyonunun kalıcı olarak engellenmesi en önemli koşul olup, antiviral ilaçlarla tedavi, siroz ve HSK gelişimini azaltmaktadır (1-3). Bununla birlikte virus genomunun hepatosit genomuna integrasyonu nedeniyle, viral replikasyon baskılansa da HSK gelişebilmektedir (4). Kronik hepatit B ilişkili HSK için ırk, yaş, cinsiyet, siroz gibi çeşitli risk faktörleri belirlenmiştir. Bunlara ek olarak viral yükün yüksek olması, viral yük düşük olsa bile yüksek titrede HBV yüzey antijeni (HBsAg) varlığı (>1000 İÜ/ml) ve "precore" veya "core" mutasyonu varlığı gibi virusla iliş-kili çeşitli faktörler de HSK gelişimiyle ilişkili bulunmuştur (5-7).Bu makalede antiviral tedavi sonrası viral baskılan-ma sağlanan ancak tedavi altında HSK gelişen bir olgu sunulmaktadır.
AbstractSuppressing viral replication is the main intervention for prevention of hepatocellular carcinoma (HCC) development, which is one of the purposes of treatment of chronic hepatitis B. We report a case of HCC in a 73-year-old woman with chronic hepatitis B who was treated and whose viral replication was successfully suppressed with antiviral therapy. The patient had anti-HBe positivity and her viral load was 1.01x10 6 IU/mL. Telbivudine treatment led to a decrease of HBV DNA below the detection limit on the second month of the treatment. But her α-fetoprotein level increased (121 ng/L) on the 30th month of the treatment. Magnetic resonance imaging showed a mass compatible with HCC on the liver and a biopsy revealed HCC. She was treated with chemo-embolization. Although viral suppression is achieved in patients with chronic hepatitis B, followup and HCC screening should be done regularly in patients who have HCC risk factors such as thrombocytopenia and older age, as in this case. Klimik Dergisi 2016; 29(3): 130-2.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.